PD-L1-deficient Mice Show That PD-L1 on T Cells, Antigen-presenting Cells, and Host Tissues Negatively Regulates T Cells
Overview
Authors
Affiliations
Both positive and negative regulatory roles have been suggested for the B7 family member PD-L1(B7-H1). PD-L1 is expressed on antigen-presenting cells (APCs), activated T cells, and a variety of tissues, but the functional significance of PD-L1 on each cell type is not yet clear. To dissect the functions of PD-L1 in vivo, we generated PD-L1-deficient (PD-L1(-/-)) mice. CD4(+) and CD8(+) T cell responses were markedly enhanced in PD-L1(-/-) mice compared with wild-type mice in vitro and in vivo. PD-L1(-/-) dendritic cells stimulated greater wild-type CD4(+) T cell responses than wild-type dendritic cells, and PD-L1(-/-) CD4(+) T cells produced more cytokines than wild-type CD4(+) T cells in vitro, demonstrating an inhibitory role for PD-L1 on APCs and T cells. In vivo CD8(+) T cell responses also were significantly enhanced, indicating that PD-L1 has a role in limiting the expansion or survival of CD8(+) T cells. Studies using the myelin oligodendrocyte model of experimental autoimmune encephalomyelitis showed that PD-L1 on T cells and in host tissues limits responses of self-reactive CD4(+) T cells in vivo. PD-L1 deficiency converted the 129S4/SvJae strain from a resistant to experimental autoimmune encephalomyelitis-susceptible strain. Transfer of encephalitogenic T cells from wild-type mice into PD-L1(-/-) recipients led to exacerbated disease. Disease was even more severe in PD-L1(-/-) recipients of PD-L1(-/-) T cells. These results demonstrate that PD-L1 on T cells, APCs, and host tissue inhibits naïve and effector T cell responses and plays a critical role in T cell tolerance.
Wellhausen J, Rohl L, Berszin M, Krucken I, Zebralla V, Pirlich M Front Immunol. 2025; 15:1473897.
PMID: 39882242 PMC: 11774711. DOI: 10.3389/fimmu.2024.1473897.
Helminth extracellular vesicles co-opt host monocytes to drive T cell anergy.
Borup A, Sharifpour M, Rossen L, Whitehead B, Boysen A, Olesen R J Extracell Vesicles. 2025; 14(1):e70027.
PMID: 39815783 PMC: 11735955. DOI: 10.1002/jev2.70027.
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.
Eshaq A, Flanagan T, Ba Abbad A, Makarem Z, Bokir M, Alasheq A Int J Mol Sci. 2025; 26(1.
PMID: 39795946 PMC: 11719825. DOI: 10.3390/ijms26010088.
Gureviciene G, Matulione J, Poskiene L, Miliauskas S, Zemaitis M Int J Mol Sci. 2024; 25(19).
PMID: 39409156 PMC: 11477418. DOI: 10.3390/ijms251910827.
Lasheen N, Allam S, Elgarawany A, Aswa D, Mansour R, Farouk Z J Physiol Sci. 2024; 74(1):46.
PMID: 39313800 PMC: 11421184. DOI: 10.1186/s12576-024-00933-4.